Ftse Mib
32.656,83
-2,84%
DAX
18.002,02
-1,43%
S&P 500
5.425,14
-0,16%
NASDAQ
17.657,07
-0,06%
Bitcoin
65.425,96
-2,00%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Prime Medicine Inc (PRME) Prime Medicine Inc (PRME) Notizie

Prime Medicine Inc

PRME
7,27
-0,63 (-7,97%)
Ultimo aggiornamento: 19:09:03
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
12/6/202422:10EDGAR2Form 8-K - Current report
30/5/202414:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
21/5/202422:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/5/202422:03EDGAR2Form 8-K - Current report
13/5/202414:00GLOBEPrime Medicine to Present at H.C. Wainwright 2nd Annual..
10/5/202414:22EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/5/202414:05EDGAR2Form 8-K - Current report
10/5/202414:00GLOBEPrime Medicine Reports First Quarter 2024 Financial Results..
08/5/202414:00GLOBEPrime Medicine Presents Preclinical Data Demonstrating..
01/5/202414:00GLOBEPrime Medicine to Participate in the 27th Annual Milken..
29/4/202413:00GLOBEPrime Medicine Announces FDA Clearance of Investigational..
23/4/202414:00GLOBEPrime Medicine to Present Preclinical Data Demonstrating..
01/3/202414:09EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/3/202414:04EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
01/3/202414:01EDGAR2Form 8-K - Current report
01/3/202414:00GLOBEPrime Medicine Reports Full Year 2023 Financial Results and..
28/2/202414:00GLOBEPrime Medicine to Participate in Upcoming Investor..
23/2/202423:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202403:31EDGAR2Form SC 13D - General statement of acquisition of beneficial..
20/2/202423:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202422:01GLOBEPrime Medicine Announces Closing of Upsized Public Offering..
16/2/202412:23EDGAR2Form 8-K - Current report
16/2/202412:17EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
15/2/202405:50GLOBEPrime Medicine Announces Pricing of Upsized Public Offering
15/2/202403:57EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
14/2/202423:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
14/2/202422:12EDGAR2Form 8-K - Current report
14/2/202422:05GLOBEPrime Medicine Announces Proposed Public Offering of Common..
25/1/202414:00GLOBEPrime Medicine Receives Up to $15 Million from Cystic..
08/1/202414:01EDGAR2Form 8-K - Current report
05/1/202423:03EDGAR2Form 8-K - Current report
05/1/202414:15EDGAR2Form 8-K - Current report
05/1/202414:00GLOBEPrime Medicine Appoints Allan Reine, M.D., as Chief..
02/1/202414:00GLOBEPrime Medicine to Present at 42nd Annual J.P. Morgan..
14/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/11/202314:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
03/11/202322:23EDGAR2Form S-3 - Registration statement under Securities Act of..
03/11/202322:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202321:06EDGAR2Form 8-K - Current report
03/11/202321:01GLOBEPrime Medicine Reports Third Quarter 2023 Financial Results..
27/10/202312:00GLOBEPrime Medicine Presents First-ever Prime Editing Data in..
24/10/202313:30GLOBEPrime Medicine Presents First In Vivo Proof-of-Concept Prime..
17/10/202314:00GLOBEPrime Medicine to Highlight Positive Preclinical..
19/9/202314:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
31/8/202314:00GLOBEPrime Medicine to Present at Upcoming Investor Conferences
07/8/202322:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:04EDGAR2Form 8-K - Current report
07/8/202322:01GLOBEPrime Medicine Reports Second Quarter 2023 Financial Results..
22/6/202314:00GLOBEPrime Medicine and Cimeio Therapeutics Announce Research..
Apertura: 7,80 Min: 7,18 Max: 7,92
Chiusura: 7,90

La tua Cronologia

NASDAQ
PRME
Prime Medicine
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network